ArticleBiomaterials translational2025
Preclinical evaluation of aligned fibrin nanofibre hydrogels in a non-human primate model of spinal cord injury: A pilot study.
Article in Biomaterials translational, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gelatin methacryloyl/hyaluronic acid hydrogel for localized ropivacaine delivery alleviates neuropathic pain and supports functional recovery after spinal cord injury.Journal of materials science. Materials in medicine · 2026Article
- Autologous Neural Stem Cell Encapsulation in CT04-Integrated Fibrin Hydrogel Enhances Tissue Regeneration After Spinal Cord Injury in Monkeys.Molecular neurobiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) often leads to partial or complete loss of motor, sensory, and autonomic functions. We have previously shown that the transplantation of hierarchically aligned fibrin nanofibre hydrogel scaffolds (AFGs) facilitates robust neuroregeneration and functional recovery in rat and dog SCI models. Given these positive results, we aimed to evaluate the biosafety and efficacy of AFGs in a non-human primate SCI model before exploring its potential in the clinic. In the present study, no significant adverse reactions were observed over 24 weeks following AFG implantation into 1-cm gaps in the hemisected thoracic spinal cords of monkeys (Macaca fascicularis). Scaffold implantation also reduced cystic cavity formation and encouraged axonal sprouting across the lesion site. Notably, detailed histological analysis demonstrated that AFG promoted high-density, sequential, and aligned nerve fibre regeneration, resulting in remyelination and vascularisation, ultimately leading to remarkable motor function recovery. These results indicate that AFG transplantation exhibits reliable biocompatibility and effectiveness in promoting spinal cord repair in a non-human primate SCI model. Owing to the similarities in genetics and physiology between non-human primates and humans, AFG transplantation therapy is likely suitable for use in human spinal cord repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.